Caitlyn McComb

Caitlyn McComb

Auto-generated profile, based on publicly available information

Caitlyn McComb

University of North Carolina at Chapel Hill 4 Lineberger Comprehensive Cancer Center, School of Medicine Chapel Hill, North Carolina

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2026 in Blood Advances
Verified
Journal Article
Closed access
EHEmily M. Harris
Emily M. Harris
MSMacGregor Steele
MacGregor Steele
TKTatiana Kalashnikova
Tatiana Kalashnikova
Sherif M. BadawySherif M. Badawy
Sherif M. Badawy
SPSureka Pavalagantharajah
Sureka Pavalagantharajah
RGRachael Grace
Rachael Grace
Pediatric autoimmune hemolytic anemia (AIHA) is a heterogeneous disease with significant morbidity due to the underlying condition and its treatment. Evidence-based guidelines for evaluation and management are lacking. Data from 399 patients with AIHA followed at 15 pediatric centers were collected to identify factors associated with secondary diagnoses, recurrent/chronic course, therapeutic efficacy, and mortality. Most had AIHA associated with secondary diagnoses including Evans syndrome (142/385 [37%]), other autoimmunity (86/392 [22%]), and inborn errors of immunity (IEI; 68/379 [18%]). Of 305 patients tested, 82% had abnormal functional immune results. Genetic testing for IEI was performed in 109 of 348 patients (31%), with pathogenic findings identified in 32% of those tested. Patients with IEI or other autoimmunity more frequently had abnormal immunoglobulin and complement testing. Prevalence of IEI was not different between those presenting with and without infection. The median number of treatments for the first AIHA episode was 2 (range, 0-17). Of those with warm AIHA, 31% received steroid-sparing therapy during the first episode. Patients with recurrent AIHA (42%) had a higher rate of abnormal immune tests (odds ratio [OR], 2.29; P = .012), Evans syndrome (OR, 4.85; P< .001), IEI (OR, 3.88; P< .001), and other autoimmune disorders (OR, 3.29; P< .001). With a median follow-up of 4.9 years (range, 0-19.4), 72 of 257 (28%) with warm AIHA continued to have active disease on treatment. Of the 399 patients, 10 died, all of whom had secondary diagnoses. Expansive immune evaluation, monitoring, and targeted treatments directed at immune diagnoses are needed for pediatric AIHA, highlighting the need for evidence-based pediatric AIHA guidelines.

15 April 2026 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
CMCaitlyn McComb
Caitlyn McComb
VPVinita Pai
Vinita Pai
JSJoseph Stanek
Joseph Stanek
ARAlexander W. Rankin
Alexander W. Rankin
MLMargaret Lamb
Margaret Lamb
HRHemalatha G. Rangarajan
Hemalatha G. Rangarajan

30 October 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
JSJustin R. Sperlazza
Justin R. Sperlazza
KFKevin C. Field
Kevin C. Field
CMCaitlyn McComb
Caitlyn McComb
ELElisa Landoni
Elisa Landoni
SPSara K. Peterson
Sara K. Peterson
IDIan J. Davis
Ian J. Davis
Adoptive cellular therapies depend on the adequate expression of target antigens on tumors. The disialoganglioside GD2, a target of chimeric antigen receptor (CAR) T cells (GD2.CAR T cells) and monoclonal antibodies, is variably expressed in Ewing sarcoma and osteosarcoma. We investigated the ability of chromatin-directed small molecules to enhance tumor GD2 and sensitize tumors to GD2.CAR T cells. Although the EZH2 inhibitor tazemetostat increased GD2 levels in culture and in xenografted mice, tazemetostat treatment was unable to maintain sufficient tumor GD2 levels necessary to enable tumor control in a metastatic xenograft model. We performed a screen of chromatin-directed small molecules to identify additional compounds capable of regulating tumor GD2 and identified multiple compounds, including the HDAC inhibitor entinostat and the DOT1L inhibitor pinometostat. Both compounds greatly enhanced tumor GD2 expression by tazemetostat in culture but did not limit CAR T-cell activity. In multiple xenograft models, the combination of tazemetostat and entinostat resulted in enhanced tumor GD2 expression and led to long-term tumor control by GD2.CAR T cells. These data offer preclinical support for the incorporation of chromatin-directed inhibitors into ongoing CAR T-cell trials for Ewing sarcoma and osteosarcoma.